In vitro activity of cysteamine against SARS-CoV-2 variants
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
-
SciScore for 10.1101/2021.10.02.462862: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Wild type and the variants stocks of SARS-CoV-2 were expanded from the seed stocks by infecting Calu-3 cells by in EMEM medium containing 2% FBS, L-glutamine and penicillin/streptomycin. Calu-3suggested: BCRJ Cat# 0264, RRID:CVCL_0609)Vero-TMPRSS2 cells (175,000 cells per well) were added into 24 well plates in DMEM medium containing 10% FBS, L-glutamine, puromycin (10 μg/ml) and penicillin/streptomycin and the plates were cultured overnight at 37°C in 5% CO2. Vero-T…SciScore for 10.1101/2021.10.02.462862: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Wild type and the variants stocks of SARS-CoV-2 were expanded from the seed stocks by infecting Calu-3 cells by in EMEM medium containing 2% FBS, L-glutamine and penicillin/streptomycin. Calu-3suggested: BCRJ Cat# 0264, RRID:CVCL_0609)Vero-TMPRSS2 cells (175,000 cells per well) were added into 24 well plates in DMEM medium containing 10% FBS, L-glutamine, puromycin (10 μg/ml) and penicillin/streptomycin and the plates were cultured overnight at 37°C in 5% CO2. Vero-TMPRSS2suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)Software and Algorithms Sentences Resources The Absolute IC50 values were calculated using GraphPad Prism 9 program choosing nonlinear regression in a Dose-Response curve. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-